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Background and purpose: The aim of this study is to derive ‘‘dose painting by numbers” prescriptions from
retrospectively observed recurrence volumes in a patient group treated with conventional radiotherapy
for head and neck squamous cell carcinoma.
Materials and methods: The spatial relation between retrospectively observed recurrence volumes and
pre-treatment standardized uptake values (SUV) from fluorodeoxyglucose positron emission tomography
(FDG-PET) imaging was determined. Based on this information we derived SUV driven dose–response
functions and used these to optimize ideal dose redistributions under the constraint of equal average
dose to the tumor volumes as for a conventional treatment. The response functions were also imple-
mented into a treatment planning system for realistic dose optimization.
Results: The calculated tumor control probabilities (TCP) increased between 0.1–14.6% by the ideal dose
redistributions for all included patients, where patients with larger and more heterogeneous tumors got
greater increases than smaller and more homogeneous tumors.
Conclusions: Dose painting prescriptions can be derived from retrospectively observed recurrence
volumes spatial relation to pre-treatment FDG-PET image data. The ideal dose redistributions could
significantly increase the TCP for patients with large tumor volumes and large spread in SUV from
FDG-PET. The results yield a basis for prospective studies to determine the clinical value for dose painting
of head and neck squamous cell carcinomas.
 2016 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2016) xxx–xxxThe radiotherapy concept ‘‘dose painting” [1] illustrates that the
dose prescription for a tumor volume could be differentiated by
functional imaging methods that map different dose–response
levels. From this concept, the term ‘‘dose painting by numbers”
[2] has evolved to distinguish that the dose prescription can be
done on a voxel level. However, detailed knowledge of how image
values relate to dose responses is largely lacking. Simple dose pre-
scription functions have been proposed, such as linear relations
within suitable dose ranges [3–13]. Other studies have taken a
more mechanistic approach to determine dose painting prescrip-
tions. As an example, Thorwarth et al. [14] modified the linear
quadratic model with a hypoxia related parameter to determine
spatially varying dose escalation factors as a basis for dose plan-
ning. By analyzing observed dose–response data from several stud-
ies, Jeong et al. [15] concluded that tumors in the head and neck
region with a high uptake of fluorodeoxyglucose (FDG) likely
require 10–30% more dose to reach the same control probabilityas tumors with a lower FDG uptake. Conclusively, it was stressed
in a review by Bentzen and Grégoire [16], that the dose painting
prescription ideally should be based on observed dose–response
data for different functional imaging methods. Such an observation
driven approach has been presented by Vogelius et al. [17], which
retrospectively analyzed a group of patients treated for head and
neck squamous cell carcinoma. Based on observed failure patterns,
they derived dose–response functions for different contours that
were distinguished by means of pre-treatment FDG-PET/CT. They
used these contour driven dose–response functions in a dose opti-
mization process to maximize the patient’s tumor control proba-
bilities (TCP) under the constraint of maintaining the average
dose as compared to a conventional treatment. However, their
approach did not take into consideration the dose–volume effect,
i.e. how differences in tumor volume would affect the patient’s
expected TCP.
In this study we present an observation driven approach for
‘‘dose painting by numbers” based on retrospectively analyzed
treatment data. Our dose painting approach is, in the same manner
as Vogelius et al. [17], based on the assumption that image data do
not directly correlate to a dose prescription, but rather to adiother
2 Probabilistic dose painting by numbersdose–response function. We demonstrate how dose–response
functions on a voxel level can be derived and how these can be
used for dose painting optimization to yield dose prescriptions.
We also study the potential gain in TCP by calculating ideal dose
redistributions and lastly we demonstrate the use of the dose–re-
sponse functions in a treatment planning system to optimize real-
istic dose redistributions.
Materials and methods
We start this chapter with a summary of the patient cohort used
as a learning set to determine dose–response data, followed by a
description of the involved mathematical procedures. We end by
giving examples of how the derived dose–response data can be
implemented for dose optimization.Patient cohort data
This study is a retrospective study based on 150 consecutive
patients treated between 2009 and 2014 at the Uppsala University
hospital with radiotherapy (RT) for head and neck squamous cell
carcinoma. The inclusion criteria were availability of pre-
treatment FDG-PET/CT imaging in treatment position, and at least
6 months of follow-up. In total 59 patients met these criteria. The
median follow up time was 19.3 months (range 6.3–65.6 months)
after the last day of RT. All these 59 patients had completed RT
with a dose to the primary clinical target volume (CTVT) between
66 and 74.5 Gy EQD2, as determined from the fractionation pat-
terns with a/b = 10. Averaged over all treated patients this yielded
a mean dose of Davg = 70.1 Gy for 35 fractions to the CTVT volumes.
In the Supplementary material we provide more information about
the CTVT volumes and their SUV distributions. In total 23 of the 59
patients relapsed after RT of which 17 had a local recurrence
within their CTVT. The median time to a local recurrence was
4.1 months (range 1.3–11.8 months). Out of the 17 locally relaps-
ing patients 5 also relapsed in a lymph node region, while 6
relapsed in a lymph node region only. The median follow up time
for the 42 patients that demonstrated local control was
24.9 months (range 7.2–65.6 months). Hence, the observed local
tumor control frequency at Davg is TCPobs = (59–17)/59 = 71.2%. To
parameterize the patient cohorts (pc) tumor control probability,
a logistic function [18] was chosen such that
TCPpcðDÞ ¼ 1
1þ D50;pcD
 4c50;pc ; ð1Þ
with c50,pc = 1.8 taken from the literature [19], and D50,pc = 61.9 Gy
determined so that TCPpc at D = Davg equal the observed TCPobs.Delineation of recurrent tumor volumes
All 17 local recurrences were confirmed by biopsies. The recur-
rence volumes (RVs) were manually delineated on the CT slices
from the pre-treatment PET/CT by an experienced radiation oncol-
ogist. To avoid biasing the delineation, none of the pre-treatment
PET images or originally delineated CTVT volumes were shown
during this process. The delineation process was supported by
informed consent using post-treatment images and follow up data,
such as physical examination of the patients and pathological
statements from biopsies. Available post-treatment images were
shown on a screen next to the one where the delineation was done.
All 17 patients had a post-treatment CT of which 13 also had a
post-treatment PET/CT. Out of these 13 patients, 7 also had a
post-treatment MRI examination. The dose painting robustness
with regard to the RV delineations was tested through use of two
additional sets of RVs that were decreased or expanded from thePlease cite this article in press as: Grönlund E et al. Dose painting by number
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new contours with a patient specific uniform distance from the
delineated contours such that the RVs were reduced to 50% of its
original volume. These decreased contours were all within a uni-
form distance of 1.0–2.5 mm from the delineated contours. The
expanded volumes were constructed by adding a margin of
3.3 mm, which corresponds to the 95 percentile of a normal distri-
bution with a standard deviation of 2 mm, assumed to be a reason-
able contouring distance uncertainty. In both cases, the new
contours were created by using 3D distance maps based on the
original contours.Derivation of SUV driven dose–response functions
We will now derive dose–response functions dependent on
absolute SUV in voxels, but this derivation formalism could also
be applied for relative image data normalized to e.g. the maximum
SUV for a patient. To model a dose–response function in principle
any parameterizable sigmoidal function can be used, but we adopt
the logistic function with the logarithm of dose as covariate [18].
This function is often used for statistical applications and we adopt
it because it forces the probability to zero when the dose goes to
zero, thus allowing a realistic behavior for large dose ranges. The
SUV specific dose–response functions to be determined will hence
be described by
TCPvoxðD; SUVÞ ¼ 1
1þ D50ðSUVÞD
 4c50;eff ; ð2Þ
where D50(SUV) is assigned to be a function of SUV and c50,eff is set
to be constant as in Vogelius et al. [17]. In the following, we show
how to determine D50(SUV) and c50,eff from voxel based recurrence
frequencies using the simplification that every CTVT voxel for all
included patients has received an equal dose of Davg (we will later
slightly relax this condition). From the 17 delineated RVs and the
59 treated CTVTs, we determine the SUV frequency distribution
fRVs(SUV) for the RVs and the SUV frequency distribution
f(RVs[CTVTs)(SUV) for the union of all RVs and CTVTs. From these
we define a local control ratio (LCR) as a function of SUV
LCRðSUVÞ ¼ 1 f RVsðSUVÞ
f ðRVs [ CTVTsÞðSUVÞ
: ð3Þ
To transform this LCR function into SUV dependent voxel speci-
fic TCPvox values we introduce a normalizing exponent k that takes
into account the used dose voxel sizes and also reconstructs the
observed tumor control TCPobs for the population. Under the
assumption of voxel independency, the TCP for a volume is calcu-
lated by multiplying the individual TCPvox values belonging to the
volume. Hence, k is determined such that
TCPvoxðDavg; SUVÞ ¼ ðLCRðSUVÞÞk; ð4Þ
and
TCPobsðDavgÞ ¼ 1N
X
pat
Y
vox2CTVTpat
TCPvoxðDavg; SUVÞ ð5Þ
are fulfilled, where Eq. (4) preserves the calculated LCR, and Eq. (5)
imposes that the average resulting TCP over all N patients equals
the observed tumor control within the patient cohort. It follows that
k will be inversely proportional to the dose voxel volume since
smaller voxels imply more multiplications needing higher TCPvox
values to preserve TCPobs and the LCR values. With k determined
from Eqs. (4) and (5), we have TCPvox values for all SUV determined
at Davg, but not for other dose values. In order to achieve a general
TCPvox = TCPvox(D, SUV) relation based on Eq. (2) so that we can
calculate each patient’s resulting TCP values based on retrospectively determined recurrence probabilities. Radiother
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Y
vox2CTVTpat
1
1þ D50ðSUVÞD
 4c50;eff ; ð6Þ
the unknowns D50(SUV) and c50,eff must be determined. To do so,
we first solve D50(SUV) from Eqs. (2) and (4) to get
D50ðSUVÞ ¼ Davg  1ðLCRðSUVÞÞk
 1
 ! 1
4c50;eff
; ð7Þ
which contains the yet unknown c50,eff. We now introduce the
requirement that at Davg the dose derivative of Eq. (6) averaged over
all N patients should equal the dose derivative of Eq. (1) for the
patient cohort, i.e.
1
N
X
pat
dðTCPpatðDÞÞ
dD

D¼Davg
¼ dðTCPpcðDÞÞ
dD

D¼Davg
; ð8Þ
which enables us to solve for c50,eff. To show that, we apply the
derivative identity
dðTCPpatðDÞÞ
dD
¼ TCPpatðDÞ
X
vox2CTVTpat
dðTCPvoxðDÞÞ
dD
TCPvoxðDÞ ; ð9Þ
on Eq. (6), and by use of Eqs. (2) and (7) we get
dðTCPvoxðDÞÞ
dD
TCPvoxðDÞ

D¼Davg
¼ c50;eff
4ð1 ðLCRðSUVÞÞkÞ
Davg
; ð10Þ
from which c50,eff can be solved by combining Eqs. (1), (8) and (10)
yielding
c50;eff ¼ c50;pc
ðD50;pc=DavgÞ4c50;pc
ð1þ ðD50;pc=DavgÞ4c50;pc Þ
2
 NP
patTCPpatðDavgÞ
P
vox2CTVTpat ð1 ðLCRðSUVÞÞ
kÞ
: ð11Þ
With c50,eff known, D50(SUV) can be determined for all SUV by
inserting c50,eff into Eq. (7). While doing that, Davg can be substi-
tuted with a more accurate dose estimate for different SUV to
reduce the effect of introducing an average Davg in the first place.
Finally, with all needed components for Eq. (2) known, we can
use Eq. (2) for dose painting optimization.Dose painting optimization
As in Vogelius et al. [17], we choose to find optimal dose redis-
tributions requiring that the average dose D for the target volumes
is kept equal to Davg. Hence, we use the SUV driven dose–responseFig. 1. (Left) Frequency distributions of SUV for all 59 CTVTs and for the 17 delineated
delineated, expanded and decreased RVs. Also shown are the linearized LCR functions, cal
equals the sum of the CTVT and RV distributions shown to the left.
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tive to maximize a patient’s tumor control probability
maximize
D
Y
vox2CTVTpat
TCPvoxðD; SUVÞ
subject to D ¼ Davg
: ð12Þ
Firstly, we want to find ideal dose redistributions not con-
strained by radiation transport phenomena causing dose correla-
tions with nearby voxels. Such ideal dose redistributions were
solved numerically by use of the FindMaximum function in Math-
ematica (Wolfram Research, Inc., Mathematica, v. 10.0, Cham-
paign, IL (2014)). Secondly, we relax this constraint to
demonstrate a dose painting example under more realistic condi-
tions by implementing Eq. (12) into a research version of a treat-
ment planning system (RayStation v. 4.6.100.10, RaySearch
Laboratories AB, Stockholm).Results
The voxel sizes for the retrospective patient data were
1.95  1.95  3.27 mm3 for the SUV grid and 3.00  3.00 
2.50 mm3 for the dose grid. We chose to base the entire analysis
on the used dose grid voxel size and hence the SUV voxels were
resampled by trilinear interpolation to fit the dose grid. The LCR
values were determined according to Eq. (3) for the different RV
delineation scenarios based on a discretization of SUV into bins
of width 1 SUV. The LCR functions decreased with increasing SUV
except for the highest observed SUV, as shown in Fig. 1. However,
with increasing SUV the number of voxels were strongly decreas-
ing and hence diminishing the significance of the LCR values at
higher SUV. To circumvent this, we used a weighted linear fit for
each delineation scenario with the frequency of respective SUV
as weights, shown in Fig. 1. The exponent k, solved according to
Eqs. (4) and (5) for the linearized LCR functions, equaled 0.00497,
0.00277 and 0.00144 for the decreased, delineated and expanded
RVs.
Fig. 2 shows the calculated D50 functions according to Eq. (7) for
the linearized LCR functions corresponding to the different delin-
eation scenarios. These are very similar to each other in spite of
the different LCR functions shown in (Fig. 1 Right), which is a con-
sequence of reconstructing the populations TCPobs with the expo-
nent k. From the D50 functions it is evident that the SUV driven
dose–response functions, as shown in Fig. 2, demonstrates an
increasing radio resistance with increasing SUV.
By optimizing according to Eq. (12), each patient received an
ideal dose redistribution as shown in Fig. 3. The individual TCP, expanded and decreased RVs. (Right) LCR calculated according to Eq. (3) for the
culated by a weighted linear fit for each delineation scenario. The weighting function
s based on retrospectively determined recurrence probabilities. Radiother
Fig. 2. (Left) D50 as a function of SUV and the determined c50,eff values solved for the linearized LCR functions for the different delineation scenarios. (Right) SUV driven dose–
response functions for the different delineation scenarios for three different SUV. At SUV = 1 and SUV = 7 are the functions for the different delineation scenarios not
distinguishable from each other, while for at SUV = 17 a slight separation is observed with the expanded RVs rightmost and the decreased RVs leftmost.
Fig. 3. (Left) The 59 patient’s ideal dose redistributions dependent on SUV within their CTVTs. (Right) Each patient’s increase in TCP by the ideal dose redistributions
compared to a homogenous dose distribution, dependent on the standard deviation of SUV multiplied by the CTVT volumes.
4 Probabilistic dose painting by numbersincreases compared to a standard treatment with a homogeneous
dose of Davg were ranging between 0.1% and 14.6%, as visualized
dependent on the standard deviation of SUV multiplied by the
CTVT volume in Fig. 3. Clearly, the potential to increase the TCP
for a patient with dose painting increases with higher SUV hetero-
geneity and larger CTVT volumes. The locally recurrent patients
had in general a higher TCP increase than the locally controlled
patients, and the locally recurrent patient with the highest TCP
increase went from 45.3% to 59.8%. The lowest TCP increase of
0.1% was observed for a locally controlled patient, with a TCP of
96.0% for a homogeneous dose distribution. The average increase
was 4.9% for the whole patient group, meaning that if all patients
were treated with their corresponding ideal dose redistribution,
the patient cohorts observed TCPobs = 71.2% would raise to 71.2
+ 4.9 = 76.1%. As expected by the very similar D50 functions from
the decreased and expanded RVs, the corresponding average TCP
increases were 76.0% and 76.3%.
To include realistic radiation transport phenomena into the
optimization, the objectives and constraints described by Eq. (12)
were implemented into RayStation, and a more realistic dose opti-
mization was performed for a patient that had an ideal dose redis-
tribution very similar to the median of all the ideal dose
redistributions. The realistic dose optimization was done by plan-
ning with 6 MV and volumetric modulated arc therapy (VMAT)
with 2 arcs completing a full rotation and letting the optimizer
iterate until an optimal solution was found. The resulting realistic
dose redistribution is demonstrated in Fig. 4, where also forPlease cite this article in press as: Grönlund E et al. Dose painting by number
Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.007comparison this patient’s ideal dose is shown. For a homogeneous
dose distribution of Davg, the expected TCP for this patient was
60.1%. The planned realistic dose redistribution resulted in a TCP
of 66.3% compared to the TCP of 67.0% using the ideal dose
redistribution.Discussion
This study presents an observation driven approach for ‘‘dose
painting by numbers” that demonstrates how dose–response func-
tions for pre-treatment image data can be derived based on post-
treatment recurrences. There are no underlying mechanistic
assumptions in the method, it is simply based on assumed sig-
moidal dose–response curves and image data observed to correlate
to recurrence locations. It is hence likely that the approach is not
limited to FDG-PET imaging, but could be applied for other imaging
methods where image data can be correlated to a spatial variation
in TCP. The derived dose–response functions are in our case, how-
ever, only valid for voxels within the CTVT volumes. To prescribe
dose for lymph node regions, the key problem is to determine
the spatially varying risk for spread, not the spatially varying risk
for a local recurrence. Therefore, we concluded that the lymph
node relapses were outside the scope of this study.
The resolution of PET is limited by partial volume effects [20]
and the cameras technical abilities. Resolution issues for PET
imaging were demonstrated by Christian et al. [21] who analyzeds based on retrospectively determined recurrence probabilities. Radiother
Fig. 4. (Left) The objective function described by Eq. (12) used for realistic dose redistribution in RayStation for one of the patient’s CTVT. (Right) The realistic dose
redistribution in relation to SUV for this patient and for comparison this patient’s ideal dose redistribution.
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phy images. However, the physical limitations due to clinical dose
delivery processes result in dose distributions with a limited reso-
lution, likely with an order of magnitude not too different from the
clinical PET resolution. Due et al. [22] observed a correlation
between FDG-uptake and recurrence locations. Our dose painting
approach is based on our own similar observations, without mak-
ing assumptions about unresolved patterns of FDG-uptake.
Another limitation lies in the manual drawing of recurrence vol-
umes on the pre-treatment CT images that affect which SUV
regions are considered to be recurrent. To test this, we decreased
and expanded the delineated RVs and calculated corresponding
LCR functions as shown in Fig. 1. By deriving dose–response func-
tions from these LCR functions and optimizing according to Eq.
(12), it was noticed that the TCP increases for the whole population
only differed by a maximum of 0.2%. This robustness with regard to
the delineations is a result of the requirements imposed by Eqs. (4)
and (5) to maintain the observed TCPobs = 71.2% for all LCR func-
tions that resulted in different normalizing exponents k.
The ideal dose redistributions shown in Fig. 3, are based on the
constraint of a mean dose of Davg = 70.1 Gy to the CTVT for each
patient. It was observed that the maximum and minimum dose
levels were varying between patients. This is explained by that a
patient with a high median SUV has less dose to spend on the high
SUV voxels, while a patient with a lowmedian SUV can spendmore
dose on these voxels. A consequence is that the use of relative SUV
instead of absolute would yield similar dose distributions. This was
confirmed by redoing the full procedure based on relative SUV
data, although with the interest of space we chose to not present
these results. For all patients, the ideal dose redistributions
increased the calculated TCP compared to a homogeneous dose,
but not all showed a significant increase. Based on the presented
dose painting approach would patients with larger tumor volumes
and greater SUV heterogeneity gain more from dose painting,
which potentially could be used as an indicator for patient
selection.
Regarding the dose–volume effect, Vogelius et al. [17] implic-
itly assumed that all patient’s TCP values are the same for a
homogeneous dose distribution and independent of any differ-
ences in tumor volume. In this study a dose–volume effect is
introduced since the TCP calculation for a patient according to
Eq. (6) is performed by each patient’s specific number of CTVT
voxels. The TCP product models the dose–volume effect, which
also is the case in the TCP modeling presented by Ebert andPlease cite this article in press as: Grönlund E et al. Dose painting by number
Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.007Hoban [23] that also assumed that voxels are controlled indepen-
dently of each other.
The presented dose optimization yielded dose levels that
exceed what is reported as a maximum tolerated dose of 86 Gy
for 35 fractions [7,10,24]. However, since the high SUV subvolumes
are relatively small, the relative gain in TCP for the whole patient
group decreases only by 0.1% by adding a maximum dose con-
straint of 86 Gy. Dose constraints or normal tissue complication
probability (NTCP) requirements are necessary to avoid exceed-
ingly high doses when using dose–response functions for opti-
mization. It is likely that other constraints are more relevant
from a medical perspective, but elaborating on these is outside
the scope of this paper.
Prospective clinical trials are needed to confirm that the pre-
sented framework for derivation of dose–response functions can
yield the indicated improvements. For example, the study from
Trani et al. [25] indicates that dose painting does not improve
tumor control for rats. In our study we did not take into consider-
ation adaptive approaches with dose prescriptions updated by
imaging between treatment fractions. However, the study from
Berwouts et al. [9] has shown the feasibility for adaptive FDG dri-
ven dose painting, and Rasmussen et al. [26] reported that pre-
treatment FDG-PET/CT gives a stable spatio-temporal basis for
dose painting of head and neck squamous cell carcinomas. A pos-
sible complication for adaptive FDG driven dose painting can be
false positive FDG uptake caused by inflammatory reactions of irra-
diated tissues.Conclusions
In this study, we have shown that dose painting prescriptions
from FDG-PET images potentially can be used to improve treat-
ment results for head and neck squamous cell carcinomas. The pos-
sible increases in tumor control probability compared to a
conventional treatment varied from 0.1% to 14.6% where the
improvements were greater for patients with large tumor volumes
and large spread in SUV. Based on our results, prospective clinical
trials could be planned to determine the clinical value and poten-
tial for dose painting of head and neck squamous cell carcinomas.Conflict of interest statement
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